Form 4: Regulus Therapeutics Director Disposes All Holdings Following Novartis Acquisition

Pascale Witz, a Director of Regulus Therapeutics Inc., has reported the disposition of all her beneficial ownership in the company's securities, effective June 25, 2025, due to the completion of the merger with Novartis AG.

Summary

• Pascale Witz, a Director of Regulus Therapeutics Inc., reported the disposition of all her beneficial ownership in the company's securities, including common stock, stock options, and preferred stock.
• This disposition occurred on June 25, 2025, as a direct result of the merger of Regulus Therapeutics Inc. with Redwood Merger Sub Inc., a wholly-owned indirect subsidiary of Novartis AG.
• Under the merger agreement, Regulus common stock was acquired for an 'Offer Price' consisting of $7.00 in cash per share (the 'Closing Amount') plus one Contingent Value Right (CVR) per share.
• Each CVR provides the right to receive an additional $7.00 in cash upon the achievement of a specified milestone.
• As part of the merger, 67,233 shares of common stock were converted into the right to receive the Offer Price.
• Various in-the-money stock options (with exercise prices less than $7.00) were canceled and converted into cash payments (based on the difference between the Closing Amount and the exercise price) plus one CVR per underlying share.
• Out-of-the-money stock options (with exercise prices equal to or greater than $7.00 but less than $14.00) were canceled and converted into one CVR per underlying share, with potential future cash payments contingent on the CVR milestone.
• 677 shares of Class A-2 Convertible Preferred Stock, convertible into 6,770 common shares, were also converted into the right to receive cash (based on the Closing Amount) plus one CVR per underlying common share.
• Following the transaction, Pascale Witz holds 0 shares of common stock and 0 derivative securities in Regulus Therapeutics Inc.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for shareholders as the company was acquired at a defined cash price with potential upside from a CVR, providing a clear exit strategy.

Positives

• Shareholders received a guaranteed cash payment of $7.00 per share, providing immediate liquidity and a defined return.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of $7.00 per share, contingent on a specific milestone achievement.
• The acquisition by Novartis AG, a major pharmaceutical company, provides a clear exit strategy for Regulus Therapeutics Inc. shareholders.

Negatives

• Regulus Therapeutics Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Novartis AG.
• Shareholders no longer participate in the future growth or potential appreciation of Regulus's underlying business beyond the CVR milestone.
• The full $14.00 per share value (cash + CVR) is not guaranteed, as the CVR payment is contingent on a future milestone.

Risks

• The Contingent Value Right (CVR) payment of $7.00 per share is not guaranteed and is contingent upon the achievement of a specific, undefined milestone. If the milestone is not met, the CVR will not pay out.
• Out-of-the-money stock options (exercise price equal to or greater than $7.00 but less than $14.00) were converted solely into CVRs, meaning their value is entirely dependent on the CVR milestone being achieved and the $14.00 threshold being met.

Future Outlook

Regulus Therapeutics Inc. is now a wholly-owned subsidiary of Novartis AG, meaning its independent operations and strategic direction have concluded. The future financial outcome for former shareholders is primarily tied to the potential achievement of the milestone associated with the Contingent Value Rights (CVRs).

Management Comments

• The merger agreement, dated April 29, 2025, facilitated a cash tender offer by Redwood Merger Sub Inc., a Novartis AG subsidiary, to acquire all outstanding shares of Regulus Therapeutics Inc. common stock.
• The acquisition price for common stock was set at $7.00 in cash per share, plus one Contingent Value Right (CVR) per share, with each CVR potentially yielding an additional $7.00 upon milestone achievement.
• Effective June 25, 2025, Regulus Therapeutics Inc. merged into Redwood Merger Sub Inc., becoming a wholly-owned subsidiary of Novartis AG, resulting in the conversion of all outstanding equity securities into the merger consideration.

Industry Context

This acquisition exemplifies a common trend in the biotechnology and pharmaceutical industries where larger, established companies like Novartis acquire smaller, innovative biotechs like Regulus Therapeutics to gain access to their pipeline assets, intellectual property, or specialized technologies. Such deals often involve contingent value rights (CVRs) to bridge valuation gaps and share future development risks or rewards, particularly for assets in clinical development.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in this acquisition is a common mechanism in biotech M&A, particularly when the acquired company's value is heavily tied to the success of specific clinical programs or regulatory approvals.
• Similar structures have been seen in deals like Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of MyoKardia, where CVRs were used to provide additional payments upon the achievement of clinical or regulatory milestones.
• The $7.00 cash upfront plus a potential $7.00 CVR represents a specific valuation for Regulus's assets, which would be assessed against the stage of its pipeline and market comparables at the time of the merger agreement.
• Without specific details on Regulus's pipeline assets and their development stage, a direct comparison to other biotech acquisitions is limited, but the structure itself aligns with industry practices for risk-sharing and incentivizing future success.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and Contingent Value Rights (CVRs) for their shares, providing liquidity and potential future upside.
• Employees: Their employment status and benefits would transition under Novartis AG's corporate structure.
• Customers/Partners: Future relationships and product development would be managed under Novartis AG's strategic direction.

Next Steps

• The primary future event for former shareholders is the potential achievement of the milestone specified in the CVR Agreement, which would trigger the contingent payment of $7.00 per CVR.

Key Dates

Keywords

Regulus Therapeutics, Novartis, Merger, Acquisition, SEC Form 4, Insider Trading, Stock Options, CVR, Contingent Value Right, Tender Offer, Biotechnology, Pharmaceuticals, Beneficial Ownership